Knight Therapeutics (TSE:GUD) Sets New 52-Week High – Here’s What Happened

Knight Therapeutics Inc. (TSE:GUD – Get Free Report)’s stock price reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as C$8.87 and last traded at C$8.62, with a volume of 146776 shares trading hands. The stock had previously closed at C$8.66.

Analyst Ratings Changes

Separately, Canaccord Genuity Group set a C$9.50 target price on Knight Therapeutics and gave the company a “buy” rating in a report on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Knight Therapeutics has a consensus rating of “Buy” and an average price target of C$9.50.

Get Knight Therapeutics alerts:

Read Our Latest Stock Report on Knight Therapeutics

Knight Therapeutics Price Performance

The company has a market capitalization of C$846.93 million, a PE ratio of 143.67, a P/E/G ratio of -1,013.50 and a beta of -0.21. The company has a current ratio of 2.32, a quick ratio of 1.79 and a debt-to-equity ratio of 8.86. The stock has a fifty day simple moving average of C$7.17 and a 200-day simple moving average of C$6.42.

Knight Therapeutics (TSE:GUD – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The company reported C$0.13 earnings per share (EPS) for the quarter. The company had revenue of C$147.59 million during the quarter. Knight Therapeutics had a return on equity of 0.73% and a net margin of 1.10%. Equities analysts anticipate that Knight Therapeutics Inc. will post 0.1009486 earnings per share for the current year.

About Knight Therapeutics

(Get Free Report)

Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company’s principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and distributing innovative pharmaceutical products, consumer health products, and medical devices in Canada and select international markets. Knight finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights.

See Also

• Five stocks we like better than Knight Therapeutics
• Navy Catalyst Ignites Odysight’s Growth Engine
• AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
• Axon Surged After Earnings and Is Still Down Over 50% From Highs
• The Event That Could Redefine Apple’s Summer Rally

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.